Ming-Hui Zhao

Peking University First Hospital Department of Nephrology, Beijing, Beijing, China;

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: A Multicenter, Randomized, Open-Label Phase 1b/2 Trial”.

Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: A Multicenter, Randomized, Open-Label Phase 1b/2 Trial

Journal of the American Society of Nephrology(2024)10.1681/asn.2024yaqz098x

N/A

0DataRank · unranked

0 citations

Alexandra P. Lewis, Hua Zhou, Hong Li Lin, Guangqun Xing, Wei Chen +22 more

The Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: Updated Results of an Ongoing, Multicenter, Randomized, Open-Label Phase 1b/2 Trial

Journal of the American Society of Nephrology(2023)10.1681/asn.20233411s1988a

N/A

0DataRank · unranked

0 citations

Zhao Cui, Alexandra P. Lewis, Hua Zhou, Hong L. Lin, Guangqun Xing +23 more

#3776 THE TYPE Ⅱ ANTI-CD20 MONOCLONAL ANTIBODY MIL62 OR CYCLOSPORINE IN CHINESE PRIMARY MEMBRANOUS NEPHROPATHY: PRELIMINARY RESULTS OF A PHASE ⅠB/Ⅱ TRIAL

Nephrology Dialysis Transplantation(2023)10.1093/ndt/gfad063c_3776

N/A

0DataRank · unranked

0 citations

Yimiao Zhang, Alexandra P. Lewis, Hua Zhou, Hongli Lin, Guangqun Xing +21 more